A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) [Time Frame: From start of the drug administration up to Week 56 (Part A) and Week 160 (Part B)]

Part A and B: Number of Participants Achieving 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI-75) Score [Time Frame: Baseline up to Week 52 (Part A) and Week 156 (Part B)]

Part A and B: Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a >=2-point Decrease from Baseline [Time Frame: Baseline up to Week 52 (Part A) and Week 156 (Part B)]